Literature DB >> 22878510

Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.

Daphne L Wang1, Kelly B Smith, Sonia Esparza, Fawn A Leigh, Alona Muzikansky, Elyse R Park, Scott R Plotkin.   

Abstract

PURPOSE: Although patients with neurofibromatosis are predisposed to multiple nerve sheath tumors that can develop anywhere in the body and cause significant morbidity (e.g., hearing loss; pain), little research has examined emotional correlates of neurofibromatosis. The purpose of this study was to examine emotional functioning among adult patients with neurofibromatosis.
METHODS: A total of 248 patients with neurofibromatosis (neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis) who received care at a specialized clinic completed validated measures to assess symptoms of depression and anxiety, level of perceived stress, and self-esteem.
RESULTS: Patients with neurofibromatosis reported significantly more symptoms of depression and anxiety, higher levels of perceived stress, and lower levels of self-esteem as compared with general population norms. No significant differences were found among patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis, and emotional functioning was not significantly associated with disease severity. However, increased symptoms of depression and anxiety, higher levels of perceived stress, and lower levels of self-esteem were associated with a higher frequency of self-reported medical visits in the past year (P values ≤0.05).
CONCLUSION: Neurofibromatosis appears to be associated with reduced emotional functioning. Although further research is needed, these findings suggest a role for a multidisciplinary treatment approach to address emotional distress among adult patients with neurofibromatosis.

Entities:  

Mesh:

Year:  2012        PMID: 22878510      PMCID: PMC3982605          DOI: 10.1038/gim.2012.85

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  34 in total

1.  Visibility of neurofibromatosis 1 and psychiatric morbidity.

Authors:  Pierre Wolkenstein; Jacques Zeller; Jean Revuz; Emmanuel Ecosse; Alain Leplège
Journal:  Arch Dermatol       Date:  2003-01

2.  Psychometric properties of the Rosenberg Self-Esteem Scale: overall and across demographic groups living within the United States.

Authors:  Samuel J Sinclair; Mark A Blais; David A Gansler; Elisabeth Sandberg; Kimberly Bistis; Alice LoCicero
Journal:  Eval Health Prof       Date:  2010-03       Impact factor: 2.651

3.  Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.

Authors:  M M Chren; R J Lasek; L M Quinn; E N Mostow; S J Zyzanski
Journal:  J Invest Dermatol       Date:  1996-11       Impact factor: 8.551

4.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

5.  Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.

Authors:  Patricia Z Page; Grier P Page; Emmanuel Ecosse; Bruce R Korf; Alain Leplege; Pierre Wolkenstein
Journal:  Am J Med Genet A       Date:  2006-09-15       Impact factor: 2.802

6.  Altered body image: appearance-related concerns of people with visible disfigurement.

Authors:  Nichola Rumsey; Alex Clarke; Paul White; Menna Wyn-Williams; Wendy Garlick
Journal:  J Adv Nurs       Date:  2004-12       Impact factor: 3.187

7.  Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention.

Authors:  R Brian Giesler; Barbara Given; Charles W Given; Susan Rawl; Patrick Monahan; Debra Burns; Faouzi Azzouz; Kristina M Reuille; Sally Weinrich; Michael Koch; Victoria Champion
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

8.  Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients.

Authors:  Yllka Kodra; Sandra Giustini; Luigina Divona; Roberto Porciello; Stefano Calvieri; Pierre Wolkenstein; Domenica Taruscio
Journal:  Dermatology       Date:  2008-12-17       Impact factor: 5.366

Review 9.  Depression and pain comorbidity: a literature review.

Authors:  Matthew J Bair; Rebecca L Robinson; Wayne Katon; Kurt Kroenke
Journal:  Arch Intern Med       Date:  2003-11-10

10.  The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated.

Authors:  R A Marrie; R Horwitz; G Cutter; T Tyry; D Campagnolo; T Vollmer
Journal:  Mult Scler       Date:  2009-01-19       Impact factor: 6.312

View more
  30 in total

1.  RASopathies are associated with a distinct personality profile.

Authors:  Varoona Bizaoui; Jessica Gage; Rita Brar; Katherine A Rauen; Lauren A Weiss
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-04-16       Impact factor: 3.568

2.  The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Scott R Plotkin; Elyse R Park
Journal:  J Neurooncol       Date:  2014-07-15       Impact factor: 4.130

3.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

4.  The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.

Authors:  Emily L Zale; Catherine Pierre-Louis; Eric A Macklin; Eric Riklin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-12-23       Impact factor: 4.130

5.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

6.  Knowledge and Self-Esteem of Individuals with Neurofibromatosis Type 1 (NF1).

Authors:  Kayla Rosnau; S Shahrukh Hashmi; Hope Northrup; John Slopis; Sarah Noblin; Myla Ashfaq
Journal:  J Genet Couns       Date:  2016-11-04       Impact factor: 2.537

7.  First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.

Authors:  Mojtaba Talaei-Khoei; Eric Riklin; Vanessa L Merker; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2016-11-29       Impact factor: 4.130

8.  Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Filippo G Giancotti; Alexander Filatov; Anna Derman; Tsivia Hochman; Judith D Goldberg; Emilio Vega; Jeffrey H Wisoff; John G Golfinos; Amanda Merkelson; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

9.  Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.

Authors:  J S Cohen; H P Levy; J Sloan; J Dariotis; B B Biesecker
Journal:  Clin Genet       Date:  2015-01-20       Impact factor: 4.438

10.  Clinical features of schwannomatosis: a retrospective analysis of 87 patients.

Authors:  Vanessa L Merker; Sonia Esparza; Miriam J Smith; Anat Stemmer-Rachamimov; Scott R Plotkin
Journal:  Oncologist       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.